EUVIMEDEUVIMED entdecken
Klinische Studie (Phase III)Randomisierte kontrollierte StudieOpen Access

CNS Efficacy of Osimertinib With or Without Chemotherapy in Epidermal Growth Factor Receptor–Mutated Advanced Non–Small-Cell Lung Cancer

Pasi A Jänne iD, David Planchard iD, Kunihiko Kobayashi iD, Ying Cheng iD, Chee Khoon Lee iD, Natalia Valdiviezo iD, Konstantin Laktionov iD, Tsung-Ying Yang, Yan Yu iD, Terufumi Kato iD, Liyan Jiang, Busyamas Chewaskulyong iD und 13 weitere

Journal of Clinical Oncology · 01.03.2024 · 42 (7) · 808-820

DOI: 10.1200/jco.23.02219 ↗

Kurz gefasst

Klinische Studie (Phase III) in der Zeitschrift Journal of Clinical Oncology, erschienen am 01.03.2024. Verfasst von Pasi A Jänne und 24 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Oncology, Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute, Boston, MA. Hauptthemen laut MEDLINE: Acrylamides, Carcinoma, Non-Small-Cell Lung, Central Nervous System Neoplasms, Indoles. Die Arbeit wurde bisher 141-mal zitiert (Crossref) und nennt 37 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE We report CNS efficacy of first-line osimertinib plus chemotherapy versus osimertinib monotherapy in patients with epidermal growth factor receptor ( EGFR)–mutated advanced non–small-cell lung cancer (NSCLC) from the phase III FLAURA2 study according to baseline CNS metastasis status. METHODS Patients were randomly assigned to osimertinib plus platinum-pemetrexed (combination) or osimertinib monotherapy until disease progression or discontinuation. Brain scans were performed in all patients at baseline and progression and at scheduled assessments until progression for patients with baseline CNS metastases; scans were assessed by neuroradiologist CNS blinded independent central review (BICR). RESULTS On the basis of baseline CNS BICR, 118 of 279 (combination) and 104 of 278 (monotherapy) randomly assigned patients had ≥one measurable and/or nonmeasurable CNS lesion and were included in the CNS full analysis set (cFAS); 40 of 118 and 38 of 104 had ≥one measurable target CNS lesion and were included in the post hoc CNS evaluable-for-response set (cEFR). In the cFAS, the hazard ratio (HR) for CNS progression or death was 0.58 (95% CI, 0.33 to 1.01). In patients without baseline CNS metastases, the HR for CNS progression or death was 0.67 (95% CI, 0.43 to 1.04). In the cFAS, CNS objective response rates (ORRs; 95% CI) were 73% (combination; 64 to 81) versus 69% (monotherapy; 59 to 78); 59% versus 43% had CNS complete response (CR). In the cEFR, CNS ORRs (95% CI) were 88% (73 to 96) versus 87% (72 to 96); 48% versus 16% had CNS CR. CONCLUSION Osimertinib plus platinum-pemetrexed demonstrated improved CNS efficacy compared with osimertinib monotherapy, including delaying CNS progression, irrespective of baseline CNS metastasis status. These data support this combination as a new first-line treatment for patients with EGFR-mutated advanced NSCLC, including those with CNS metastases.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AcrylamidesCarcinoma, Non-Small-Cell LungCentral Nervous System NeoplasmsIndolesLung NeoplasmsPyrimidinesHumansAniline CompoundsErbB ReceptorsMutationPemetrexedPlatinumProtein Kinase Inhibitors

Substanzen

AcrylamidesAniline CompoundsErbB ReceptorsIndolesosimertinibPemetrexedPlatinumProtein Kinase InhibitorsPyrimidines

Autor:innen und Institutionen

  • Department of Medical Oncology, Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute, Boston, MA.
  • Department of Medical Oncology, Thoracic Group and International Center for Thoracic Cancers (CICT), Gustave Roussy, Villejuif, France.
  • Faculty of Medicine, Paris-Saclay University, Paris, France.
  • Department of Respiratory Medicine, Saitama Medical University International Medical Center, Hidaka, Japan.
  • Department of Thoracic Oncology, Jilin Cancer Hospital, Changchun, China.
  • Department of Medical Oncology, Cancer Care Centre, St George Hospital, Kogarah, NSW, Australia.

ORCID-Profile: Pasi A Jänne, David Planchard, Kunihiko Kobayashi, Ying Cheng, Chee Khoon Lee, Natalia Valdiviezo, Konstantin Laktionov, Yan Yu, Terufumi Kato, Busyamas Chewaskulyong, Sarayut Lucien Geater, Toshiaki Takahashi, Kentaro Tanaka, Neha P Amin, Ammar Ahmed Chaudhry, James Chih-Hsin Yang

Zitieren

APA

Jänne, P. A., Planchard, D., Kobayashi, K., Cheng, Y., Lee, C. K., Valdiviezo, N., Laktionov, K., Yang, T. Y., Yu, Y., Kato, T., Jiang, L., Chewaskulyong, B., Lucien Geater, S., Maurel, J. M., Rojas, C., Takahashi, T., Havel, L., Shepherd, F. A., Tanaka, K., …, & Yang, J. C. (2024). CNS Efficacy of Osimertinib With or Without Chemotherapy in Epidermal Growth Factor Receptor–Mutated Advanced Non–Small-Cell Lung Cancer. Journal of Clinical Oncology, 42(7), 808-820. https://doi.org/10.1200/jco.23.02219

Vancouver

Jänne PA, Planchard D, Kobayashi K, Cheng Y, Lee CK, Valdiviezo N, et al. CNS Efficacy of Osimertinib With or Without Chemotherapy in Epidermal Growth Factor Receptor–Mutated Advanced Non–Small-Cell Lung Cancer. Journal of Clinical Oncology. 2024;42(7):808-820. doi:10.1200/jco.23.02219

BibTeX
@article{Jnne2024,
  author = {Jänne, Pasi A and Planchard, David and Kobayashi, Kunihiko and Cheng, Ying and Lee, Chee Khoon and Valdiviezo, Natalia and Laktionov, Konstantin and Yang, Tsung-Ying and Yu, Yan and Kato, Terufumi and Jiang, Liyan and Chewaskulyong, Busyamas and Lucien Geater, Sarayut and Maurel, Jean-Marc and Rojas, Carlos and Takahashi, Toshiaki and Havel, Libor and Shepherd, Frances A and Tanaka, Kentaro and Ghiorghiu, Dana and Amin, Neha P and Armenteros-Monterroso, Elena and Huang, Xiangning and Chaudhry, Ammar Ahmed and Yang, James Chih-Hsin},
  title = {CNS Efficacy of Osimertinib With or Without Chemotherapy in Epidermal Growth Factor Receptor–Mutated Advanced Non–Small-Cell Lung Cancer},
  journal = {Journal of Clinical Oncology},
  year = {2024},
  volume = {42},
  number = {7},
  pages = {808--820},
  doi = {10.1200/jco.23.02219}
}
Kostenlos starten →